The North America Wound Debridement Market should witness market growth of 5.0% CAGR during the forecast period (2022-2028).
Chronic wounds or chronic lower extremity ulcers do not heal progressively by using standard treatment and medications. As a consequence, chronic wounds pose a significant challenge to the healthcare system. Such wounds require extra care and specific treatment methods like wound debridement.
These wounds can be categorized as diabetic ulcers, vascular ulcers, and pressure ulcers (PUs). All these types of wounds share some common features like excessive or prolonged inflammation, formation of drug-resistant biofilms, response inability of epidermal and dermal cells to reparative stimuli, and persistent infections.
These pathophysiologic phenomena hinder the healing process of the wound. The only difference in all kinds of chronic wounds is in their underlying pathologies. As a result, to get improved clinical outcomes, it is necessary to address and understand the difficulties that arise in chronic wound treatments. This would subsequently help in reducing the cost of healthcare and improving the quality of life of patients.
The growing ulcer incidence in the region is the most prominent factor that raises the requirement for wound debridement products. For example, the Centers for Disease Control and Prevention (CDC) of the United States of America stated that approximately 37.3 million individuals in the nation suffer from diabetes. This has increased the prevalence of diabetic foot ulcers and venous ulcers among the general population.
The US market dominated the North America Wound Debridement Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1, 650.7 million by 2028. The Canada market is poised to grow at a CAGR of 7.4% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 6.5% during (2022-2028).
Based on Mode of Purchase, the market is segmented into Prescription, Over The Counter and Others. Based on Product, the market is segmented into Medical Gauzes, Gels, Surgical Devices, Ultrasonic Devices, Ointments & Creams and Others. Based on Method, the market is segmented into Surgical, Autolytic, Enzymatic, Mechanical and Others. Based on Wound Type, the market is segmented into Diabetic Foot Ulcers, Pressure Ulcers, Burn Wounds and Venous Leg Ulcers & Others. Based on End-use, the market is segmented into Hospitals, Homecare and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include 3M Company, Coloplast Group, Medline Industries, Inc., Smith & Nephew PLC, Medtronic PLC, ConvaTec Group PLC, Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.), Johnson & Johnson (Ethicon, Inc.), Baxter International, Inc., and Molnlycke Health Care AB.
Chronic wounds or chronic lower extremity ulcers do not heal progressively by using standard treatment and medications. As a consequence, chronic wounds pose a significant challenge to the healthcare system. Such wounds require extra care and specific treatment methods like wound debridement.
These wounds can be categorized as diabetic ulcers, vascular ulcers, and pressure ulcers (PUs). All these types of wounds share some common features like excessive or prolonged inflammation, formation of drug-resistant biofilms, response inability of epidermal and dermal cells to reparative stimuli, and persistent infections.
These pathophysiologic phenomena hinder the healing process of the wound. The only difference in all kinds of chronic wounds is in their underlying pathologies. As a result, to get improved clinical outcomes, it is necessary to address and understand the difficulties that arise in chronic wound treatments. This would subsequently help in reducing the cost of healthcare and improving the quality of life of patients.
The growing ulcer incidence in the region is the most prominent factor that raises the requirement for wound debridement products. For example, the Centers for Disease Control and Prevention (CDC) of the United States of America stated that approximately 37.3 million individuals in the nation suffer from diabetes. This has increased the prevalence of diabetic foot ulcers and venous ulcers among the general population.
The US market dominated the North America Wound Debridement Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1, 650.7 million by 2028. The Canada market is poised to grow at a CAGR of 7.4% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 6.5% during (2022-2028).
Based on Mode of Purchase, the market is segmented into Prescription, Over The Counter and Others. Based on Product, the market is segmented into Medical Gauzes, Gels, Surgical Devices, Ultrasonic Devices, Ointments & Creams and Others. Based on Method, the market is segmented into Surgical, Autolytic, Enzymatic, Mechanical and Others. Based on Wound Type, the market is segmented into Diabetic Foot Ulcers, Pressure Ulcers, Burn Wounds and Venous Leg Ulcers & Others. Based on End-use, the market is segmented into Hospitals, Homecare and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include 3M Company, Coloplast Group, Medline Industries, Inc., Smith & Nephew PLC, Medtronic PLC, ConvaTec Group PLC, Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.), Johnson & Johnson (Ethicon, Inc.), Baxter International, Inc., and Molnlycke Health Care AB.
Scope of the Study
By Mode of Purchase
- Prescription
- Over The Counter
- Others
By Product
- Medical Gauzes
- Gels
- Surgical Devices
- Ultrasonic Devices
- Ointments & Creams
- Others
By Method
- Surgical
- Autolytic
- Enzymatic
- Mechanical
- Others
By Wound Type
- Diabetic Foot Ulcers
- Pressure Ulcers
- Burn Wounds
- Venous Leg Ulcers & Others
By End-use
- Hospitals
- Homecare
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- 3M Company
- Coloplast Group
- Medline Industries, Inc.
- Smith & Nephew PLC
- Medtronic PLC
- ConvaTec Group PLC
- Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.)
- Johnson & Johnson (Ethicon, Inc.)
- Baxter International, Inc.
- Molnlycke Health Care AB
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. North America Wound Debridement Market by Mode of Purchase
Chapter 5. North America Wound Debridement Market by Product
Chapter 6. North America Wound Debridement Market by Method
Chapter 7. North America Wound Debridement Market by Wound Type
Chapter 8. North America Wound Debridement Market by End-use
Chapter 9. North America Wound Debridement Market by Country
Chapter 10. Company Profiles
Companies Mentioned
- 3M Company
- Coloplast Group
- Medline Industries, Inc.
- Smith & Nephew PLC
- Medtronic PLC
- ConvaTec Group PLC
- Integra LifeSciences Holdings Corporation (Derma Sciences, Inc.)
- Johnson & Johnson (Ethicon, Inc.)
- Baxter International, Inc.
- Molnlycke Health Care AB
Methodology
LOADING...